0 results available. Select is focused ,type to refine list, press Down to open the menu,
Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The compan...
The following section summarizes insights on Inozyme Pharma Inc's Diluted EPS Incl Extra Items:
We've identified the following companies as similar to Inozyme Pharma Inc because they operate in a related industry or sector. We also considered size, growth, and various financial metrics to narrow down the list to the ones listed below.
To view the full list of supported financial metrics please see Complete Metrics Listing.
Metrics similar to Diluted EPS Incl Extra Items in the financials category include:
Company's net earnings or losses from continuing operations adjusted for certain one-time items on a per diluted share basis.
Inozyme Pharma reported diluted eps of -1.62 for the latest twelve months ending December 31, 2024 on its income statement.
Diluted EPS Incl Extra Items measures the amount of earnings per outstanding share of common stock for a company.
Basic Net Income = Net Income - Preferred Dividends
Diluted EPS = Basic Net Income / Diluted Shares Outstanding
Diluted EPS differs from Basic EPS. Basic EPS does not take into account the impact of dilutive securities like stock options or convertible bonds that a company may have in its financing structure
The tables below summarises Inozyme Pharma’s diluted eps over the last five years:
| Fiscal Year | Diluted EPS |
|---|---|
| 2020-12-31 | -5.11 |
| 2021-12-31 | -2.40 |
| 2022-12-31 | -1.78 |
| 2023-12-31 | -1.37 |
| 2024-12-31 | -1.62 |
The tables below summarizes Inozyme Pharma’s diluted eps over the last four quarters:
| Quarter Ending | Diluted EPS |
|---|---|
| 2024-03-31 | -0.38 |
| 2024-06-30 | -0.44 |
| 2024-09-30 | -0.39 |
| 2024-12-31 | -0.42 |
The chart above depicts the distribution of diluted eps incl extra items for companies operating in the Healthcare sector in the Developed economic region. Over 2,470 companies were considered in this analysis, and 2,376 had meaningful values. The average diluted eps incl extra items of companies in the sector is -1.23 with a standard deviation of 4.27.
Inozyme Pharma Inc's Diluted EPS Incl Extra Items of -1.62 ranks in the 20.5% percentile for the sector. The following table provides additional summary stats:
| Economic Risk Region | Developed |
| Total Constituents | 2,474 |
| Included Constituents | 2,376 |
| Min | -38.52 |
| Max | 7.56 |
| Median | -0.11 |
| Mean | -1.23 |
| Standard Deviation | 4.27 |
You can find companies with similar diluted eps incl extra items using this stock screener.